The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Tumor heterogeneity: Causes and consequences
Open accessAbstract
With rare exceptions, spontaneous tumors originate from a single cell. Yet, at the time of clinical diagnosis, the majority of human tumors display startling heterogeneity in many morphological and physiological features, such as expression of cell surface receptors, proliferative and angiogenic potential. To a substantial extent, this heterogeneity might be attributed to morphological and epigenetic plasticity, but there is also strong evidence for the co-existence of genetically divergent tumor cell clones within tumors. In this perspective, we summarize the sources of intra-tumor phenotypic heterogeneity with emphasis on genetic heterogeneity. We review experimental evidence for the existence of both intra-tumor clonal heterogeneity as well as frequent evolutionary divergence between primary tumors and metastatic outgrowths. Furthermore, we discuss potential biological and clinical implications of intra-tumor clonal heterogeneity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Axelrod, R., & Hamilton, W. D. (1981) · Science · doi:10.1126/science.7466396 · Cited by 20,065
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
The Neutral Theory of Molecular Evolution
Kimura, M. (1979) · Scientific American · doi:10.1038/scientificamerican1179-98 · Cited by 7,666
Mechanisms of Maintenance of Species Diversity
Chesson, P. (2000) · Annual Review of Ecology and Systematics · doi:10.1146/annurev.ecolsys.31.1.343 · Cited by 6,645
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“Intensive studies in the field of cancer genetics, and recent sequencing of cancer genomes [49–51] allowed the identification of cancer-type-specific subsets of genes that “drive” cancer progression.”
BackgroundA cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Immunobiology: the immune system in health and disease
(1995) · Choice Reviews Online · doi:10.5860/choice.32-3876 · Cited by 4,110
Cited by
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
Self-citationIntratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Visvader, J. E. (2011) · Nature · doi:10.1038/nature09781 · Cited by 1,449
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
“The complexities associated with species-barrier issues are further complicated when considering the heterogeneity of human disease.(122,123) Fortunately, efforts to correlate human and small animal data are increasing given the increasing number of clinical trials.”
BackgroundHeterogeneity in breast cancer
Polyak, K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60534 · Cited by 1,006
Self-citationCancer heterogeneity: implications for targeted therapeutics
Fisher, R., Pusztai, L., & Swanton, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.581 · Cited by 978
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review)
ZHENG, J. (2012) · Oncology Letters · doi:10.3892/ol.2012.928 · Cited by 963
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44745 · Cited by 911
Self-citationGenetic variegation of clonal architecture and propagating cells in leukaemia
Anderson, K., Lutz, C., van Delft, F. W., Bateman, C. M., Guo, Y., Colman, S. M., Kempski, H., Moorman, A. V., Titley, I., Swansbury, J., et al. (2011) · Nature · doi:10.1038/nature09650 · Cited by 806
Molyneux, G., Geyer, F. C., Magnay, F.-A., McCarthy, A., Kendrick, H., Natrajan, R., MacKay, A., Grigoriadis, A., Tutt, A., Ashworth, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.010 · Cited by 794
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
Andor, N., Graham, T. A., Jansen, M., Xia, L. C., Aktipis, C. A., Petritsch, C., Ji, H. P., & Maley, C. C. (2016) · Nature Medicine · doi:10.1038/nm.3984 · Cited by 768
Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival
Beck, A. H., Sangoi, A. R., Leung, S., Marinelli, R. J., Nielsen, T. O., van de Vijver, M. J., West, R. B., van de Rijn, M., & Koller, D. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002564 · Cited by 763
Pham, D., Tan, X., Balderson, B., Xu, J., Grice, L. F., Yoon, S., Willis, E. F., Tran, M., Lam, P. Y., Raghubar, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43120-6 · Cited by 730
Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor
Xu, X., Hou, Y., Yin, X., Bao, L., Tang, A., Song, L., Li, F., Tsang, S., Wu, K., Wu, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.025 · Cited by 667
Defining the mode of tumour growth by clonal analysis
Driessens, G., Beck, B., Caauwe, A., Simons, B. D., & Blanpain, C. (2012) · Nature · doi:10.1038/nature11344 · Cited by 717
Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
Snuderl, M., Fazlollahi, L., Le, L. P., Nitta, M., Zhelyazkova, B. H., Davidson, C. J., Akhavanfard, S., Cahill, D. P., Aldape, K. D., Betensky, R. A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.005 · Cited by 707
Single-cell dissection of transcriptional heterogeneity in human colon tumors
Dalerba, P., Kalisky, T., Sahoo, D., Rajendran, P. S., Rothenberg, M. E., Leyrat, A. A., Sim, S., Okamoto, J., Johnston, D. M., Qian, D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.2038 · Cited by 703
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660
Metronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 659
Understanding and targeting cancer stem cells: therapeutic implications and challenges
Chen, K., Huang, Y.-H., & Chen, J.-L. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.27 · Cited by 608
Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity
Marusyk, A., Tabassum, D. P., Altrock, P. M., Almendro, V., Michor, F., & Polyak, K. (2014) · Nature · doi:10.1038/nature13556 · Cited by 597
Self-citationThe transcriptional landscape and mutational profile of lung adenocarcinoma
Seo, J.-S., Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, J. K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J.-O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 584
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581
Histological types of breast cancer: How special are they?
Weigelt, B., Geyer, F. C., & Reis-Filho, J. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.004 · Cited by 572
Barkley, D., Moncada, R., Pour, M., Liberman, D. A., Dryg, I., Werba, G., Wang, W., Baron, M., Rao, A., Xia, B., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01141-9 · Cited by 532
Tumorigenesis: it takes a village
Tabassum, D. P., & Polyak, K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3971 · Cited by 564
Self-citationPaediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 529
RetractedCellular Heterogeneity and Molecular Evolution in Cancer
Almendro, V., Marusyk, A., & Polyak, K. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163923 · Cited by 498
Self-citationQuantum dots as a platform for nanoparticle drug delivery vehicle design
Probst, C. E., Zrazhevskiy, P., Bagalkot, V., & Gao, X. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.036 · Cited by 466
Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers
Cleary, A. S., Leonard, T. L., Gestl, S. A., & Gunther, E. J. (2014) · Nature · doi:10.1038/nature13187 · Cited by 465
Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells
Notta, F., Mullighan, C. G., Wang, J. C. Y., Poeppl, A., Doulatov, S., Phillips, L. A., Ma, J., Minden, M. D., Downing, J. R., & Dick, J. E. (2011) · Nature · doi:10.1038/nature09733 · Cited by 463
Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells
Wang, Y. Y., Attané, C., Milhas, D., Dirat, B., Dauvillier, S., Guerard, A., Gilhodes, J., Lazar, I., Alet, N., Laurent, V., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.87489 · Cited by 455
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 454
Luo, C., Sun, J., Liu, D., Sun, B., Miao, L., Musetti, S., Li, J., Han, X., Du, Y., Li, L., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b01632 · Cited by 443
Genetic Interactions in Cancer Progression and Treatment
Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 426
Schillaci, O., Fontana, S., Monteleone, F., Taverna, S., Di Bella, M. A., Di Vizio, D., & Alessandro, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-05002-y · Cited by 424
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Gerlinger, M., & Swanton, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605912 · Cited by 421
PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors
Deshwar, A. G., Vembu, S., Yung, C. K., Jang, G. H., Stein, L., & Morris, Q. (2015) · Genome Biology · doi:10.1186/s13059-015-0602-8 · Cited by 418
Cancer cell metabolism: implications for therapeutic targets
Jang, M., Kim, S. S., & Lee, J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.85 · Cited by 397
Tumor Redox Heterogeneity‐Responsive Prodrug Nanocapsules for Cancer Chemotherapy
Wang, J., Sun, X., Mao, W., Sun, W., Tang, J., Sui, M., Shen, Y., & Gu, Z. (2013) · Advanced Materials · doi:10.1002/adma.201300929 · Cited by 395
Spatial regulation of receptor tyrosine kinases in development and cancer
Casaletto, J. B., & McClatchey, A. I. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3277 · Cited by 359
Ling, S., Hu, Z., Yang, Z., Yang, F., Li, Y., Lin, P., Chen, K., Dong, L., Cao, L., Tao, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519556112 · Cited by 352
Tumor evolution: Linear, branching, neutral or punctuated?
Davis, A., Gao, R., & Navin, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.003 · Cited by 352
Breast cancer intra-tumor heterogeneity
Martelotto, L. G., Ng, C. K., Piscuoglio, S., Weigelt, B., & Reis-Filho, J. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3658 · Cited by 332
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
Gast, C. E., Silk, A. D., Zarour, L., Riegler, L., Burkhart, J. G., Gustafson, K. T., Parappilly, M. S., Roh-Johnson, M., Goodman, J. R., Olson, B., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat7828 · Cited by 326
Metabolic origins of spatial organization in the tumor microenvironment
Carmona-Fontaine, C., Deforet, M., Akkari, L., Thompson, C. B., Joyce, J. A., & Xavier, J. B. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700600114 · Cited by 323
Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells
Shi, Q., Qin, L., Wei, W., Geng, F., Fan, R., Shik Shin, Y., Guo, D., Hood, L., Mischel, P. S., & Heath, J. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110865109 · Cited by 318
The evolution of tumour phylogenetics: principles and practice
Schwartz, R., & Schäffer, A. A. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.170 · Cited by 318
McDermott, M., Eustace, A. J., Busschots, S., Breen, L., Crown, J., Clynes, M., O’Donovan, N., & Stordal, B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00040 · Cited by 315
Time to abandon single-site irradiation for inducing abscopal effects
Brooks, E. D., & Chang, J. Y. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 313
The Role of the Microenvironment in Mammary Gland Development and Cancer
Polyak, K., & Kalluri, R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003244 · Cited by 311
Self-citationHigh‐throughput sequencing for biology and medicine
Soon, W. W., Hariharan, M., & Snyder, M. P. (2013) · Molecular Systems Biology · doi:10.1038/msb.2012.61 · Cited by 304
Intratumor and Intertumor Heterogeneity in Melanoma
Grzywa, T. M., Paskal, W., & Włodarski, P. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.09.007 · Cited by 299
Fatty acid synthase (FASN) as a therapeutic target in breast cancer
Menendez, J. A., & Lupu, R. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1381087 · Cited by 293
Molecularly targeted cancer therapy: some lessons from the past decade
Huang, M., Shen, A., Ding, J., & Geng, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.004 · Cited by 291
Therapy resistance mediated by cancer stem cells
Steinbichler, T. B., Dudás, J., Skvortsov, S., Ganswindt, U., Riechelmann, H., & Skvortsova, I.-I. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.11.006 · Cited by 286
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
Koren, S., & Bentires-Alj, M. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.031 · Cited by 284
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Almendro, V., Cheng, Y.-K., Randles, A., Itzkovitz, S., Marusyk, A., Ametller, E., Gonzalez-Farre, X., Muñoz, M., Russnes, H. G., Helland, Å., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.041 · Cited by 274
Self-citationEpigenetic heterogeneity in cancer
Guo, M., Peng, Y., Gao, A., Du, C., & Herman, J. G. (2019) · Biomarker Research · doi:10.1186/s40364-019-0174-y · Cited by 270
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
Dobrolecki, L. E., Airhart, S. D., Alferez, D. G., Aparicio, S., Behbod, F., Bentires-Alj, M., Brisken, C., Bult, C. J., Cai, S., Clarke, R. B., et al. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9653-x · Cited by 267
Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer
Tang, Y., Wang, Y., Kiani, M. F., & Wang, B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.05.012 · Cited by 265
Alternative mechanisms of miR-34a regulation in cancer
Slabáková, E., Culig, Z., Remšík, J., & Souček, K. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.495 · Cited by 264
Three-dimensional in vitro culture models in oncology research
Jubelin, C., Muñoz-Garcia, J., Griscom, L., Cochonneau, D., Ollivier, E., Heymann, M.-F., Vallette, F. M., Oliver, L., & Heymann, D. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00887-3 · Cited by 264
Roles of circRNAs in the tumour microenvironment
Zhang, Q., Wang, W., Zhou, Q., Chen, C., Yuan, W., Liu, J., Li, X., & Sun, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1125-9 · Cited by 260
Hinohara, K., Wu, H.-J., Vigneau, S., McDonald, T. O., Igarashi, K. J., Yamamoto, K. N., Madsen, T., Fassl, A., Egri, S. B., Papanastasiou, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.014 · Cited by 255
“Despite the importance of intratumor phenotypic heterogeneity for tumor progression and therapy resistance (Marusyk et al., 2012; Marusyk and Polyak, 2010), our understanding of regulators of this process and our ability to modulate them are very limited.”
Targeted enrichment of genomic DNA regions for next-generation sequencing
Mertes, F., ElSharawy, A., Sauer, S., van Helvoort, J. M. L. M., van der Zaag, P. J., Franke, A., Nilsson, M., Lehrach, H., & Brookes, A. J. (2011) · Briefings in Functional Genomics · doi:10.1093/bfgp/elr033 · Cited by 253
Microfluidic 3D models of cancer
Sung, K. E., & Beebe, D. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.002 · Cited by 190
Carey, S. P., Starchenko, A., McGregor, A. L., & Reinhart-King, C. A. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9565-x · Cited by 174
“Our results demonstrate a previously unappreciated instance of intratumor cellular cooperation [4] whereby invasion-competent cancer cells could provide ready-made matrix tunnels to be used by other cells that otherwise lack the ability to invade and negotiate the stromal ECM.”
BackgroundDevelopment of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
“Additionally, heterogeneity of target expression has been observed within a given tumor or metastasis [32] and this is thought to be a mechanism of developing resistance to targeted therapies; non-target expressing cells survive treatment and clonally expand into a resistant population.”
BackgroundPyruvate and metabolic flexibility: illuminating a path toward selective cancer therapies
Olson, K. A., Schell, J. C., & Rutter, J. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.01.002 · Cited by 154
Robust covariance and scatter matrix estimation under Huber’s contamination model
Chen, M., Gao, C., & Ren, Z. (2018) · The Annals of Statistics · doi:10.1214/17-aos1607 · Cited by 146
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery
Jurczyk, M., Jelonek, K., Musiał-Kulik, M., Beberok, A., Wrześniok, D., & Kasperczyk, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030326 · Cited by 133
Tumor-on-a-chip for integrating a 3D tumor microenvironment: chemical and mechanical factors
Wan, L., Neumann, C. A., & LeDuc, P. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00550a · Cited by 120
Wang, Y. “., Reder, N. P., Kang, S., Glaser, A. K., Yang, Q., Wall, M. A., Javid, S. H., Dintzis, S. M., & Liu, J. T. C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0709 · Cited by 104
Zhou, J. X., Taramelli, R., Pedrini, E., Knijnenburg, T., & Huang, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09307-w · Cited by 85
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer
Blagden, S. P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00149 · Cited by 66
Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models
Cox, M. C., Mendes, R., Silva, F., Mendes, T. F., Zelaya-Lazo, A., Halwachs, K., Purkal, J. J., Isidro, I. A., Félix, A., Boghaert, E. R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97894-0 · Cited by 58
Generative Artificial Intelligence in Anatomic Pathology
Brodsky, V., Ullah, E., Bychkov, A., Song, A. H., Walk, E. E., Louis, P., Rasool, G., Singh, R. S., Mahmood, F., Bui, M. M., et al. (2025) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2024-0215-ra · Cited by 48
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
Chambliss, A. B., Wu, P., Chen, W., Sun, S. X., & Wirtz, D. (2013) · The FASEB Journal · doi:10.1096/fj.12-227108 · Cited by 34
“Tumors can consist of heterogeneous cell subpopulations (16, 17), each of which may react to drugs differently, thus creating a large obstacle to overcome for the development of successful treatments.”
BackgroundEngineering cell heterogeneity into organs-on-a-chip
Mertz, D. R., Ahmed, T., & Takayama, S. (2018) · Lab on a Chip · doi:10.1039/c8lc00413g · Cited by 33
Woo, J., Loycano, M., Amanullah, M., Qian, J., Amend, S. R., Pienta, K. J., & Zhang, H. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.100949 · Cited by 17
Metadata
- Authors
- Marusyk, A., & Polyak, K.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 1805
- Issue
- 1
- Pages
- 105-117
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W2067256262
- Cited by
- 1,602
- References
- 134
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.